WuXi XDC Partners with Multitude Therapeutics and Hyslink to Accelerate ADC Drug Discovery with Novel Toxin-Linker Technology

ShanghaiJanuary 31, 2024PR Newswire -- WuXi XDC (2268.HK), a global leading CRDMO service provider focused on end-to-end services for antibody-drug conjugates (ADC) and other bioconjugate drugs, announced a collaboration with Multitude Therapeutics, a clinical-stage platform company dedicated to ADC drug development. Additionally, WuXi XDC signed a Memorandum of Understanding (MOU) with HySlink Therapeutics, an ADC drug research company, to establish a comprehensive collaboration on novel toxin-linker technologies and CRDMO services for the research, development, and manufacturing of ADCs.

WuXi XDC provides a highly integrated one-stop bioconjugate drug development platform and end-to-end CRDMO services. Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd., as a strategic partner of WuXi XDC, offers its T-Moiety linker technology co-developed with HySlink Therapeutics. Both parties will leverage their respective strengths to build a more efficient ADC technology platform from the perspectives of novel T-Moiety linkers, combination with camptothecin toxin derivatives, and high DAR values. This collaboration aims to empower clients to accelerate the discovery of preclinical ADC candidate molecules (PCC) and develop more novel bioconjugate drugs, improving development efficiency and success rates.

Dr. Jincai Li, CEO of WuXi XDCPuzhong Discovery and HySlink Therapeutics have jointly developed a novel T-Moiety linker technology, which integrates with our open conjugation technology platform. This will empower customers to rapidly deliver preclinical candidates for T moiety - exatecan ADCs and enhance R&D efficiency. We are delighted to collaborate with industry partners to continuously innovate and upgrade our platform technologies and capabilities based on customer needs. Leveraging our professional expertise, we aim to build a world-leading conjugation process platform that fully empowers the bioconjugate pharmaceutical industry in terms of height, breadth, and depth.

Puzhong Discovery and HySlink TherapeuticsRepresentation，WuXi XDC has rich experience and outstanding capabilities in the CRDMO business field.Both partiesWe are glad to have a strong alliance in the technical field,ItsThe proprietary novel T-Moiety linker can significantly enhance the therapeutic efficacy of ADCs. With higher linker stability and hydrophilic shielding effects, it improves the overall stability of antibody-drug conjugates, prolongs drug action time, and has the potential to overcome multidrug tumor resistance. Without increasing toxic side effects, it further expands the therapeutic window of existing ADC drugs (related research findings were published in Cancer Discovery 2023;13(4):950-73).This timeThe collaboration will help more ADC development companies stably and rapidly obtain such payloads-linkers, benefiting more patients.

About WuXi XDC (WuXi XDC）

WuXi XDC (Stock Code: 2268.HK, hereinafter referred to as "WuXi XDC") is a global leading contract research, development, and manufacturing organization (CRDMO) for bioconjugate drugs, focusing on providing end-to-end services for antibody-drug conjugates (ADCs) and other bioconjugate drugs. Services cover various areas of R&D and GMP production, including antibody intermediates and other conjugated biologics, linkers/chemical payloads, conjugate drug substances, and formulations. For more information, please visit:wuxixdc.com。

Contact Information

Investor Relations:wuxixdc.ir@wuxibiologics.com
Media Inquiry:wuxixdc_pr@wuxibiologics.com
Business Development:wuxixdc_info@wuxibiologics.com

About Puzhong Discovery

Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. is a clinical-stage company focused on the development of ADC drugs. The company's founders have a track record of continuous successful entrepreneurial experiences. Puzhong Discovery has the capability to develop industry-leading ADC products, with its competitive advantage lying in two technological platforms: MabArray™ (Sci Adv. 2020 6(11): EAAX2271) — an antibody platform for discovering novel cell surface anti-tumor targets to construct First-in-Class targets, and T1000 — a novel linker/payload technology for ADC development. ADCs prepared using this platform achieve a more optimized balance in terms of bystander effect, efficacy, and safety. The combination of MabArray™ and T1000 generates significant synergistic effects, enabling Puzhong Discovery to build an ADC "catalog" that holds promise for treating malignant tumors with high unmet therapeutic needs and achieving higher and more durable responses.

Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. was named one of the "Top 50 Innovative and Entrepreneurial Enterprises" in the finals of China Innovation and Entrepreneurship Competition 2023. It has received numerous honors, including being a high-tech enterprise, a "Science and Technology Little Giant" cultivation enterprise in Shanghai, a corporate technology center in Xuhui District, one of the "Top 50 Most Investable Startups in Shanghai" in the 2020 Maker China competition, and one of the "Top 50 Most Innovative Biomedical Enterprises in China." Its investors include well-known institutions such as Genesis Capital, Northern Light Venture Capital, Cowin Venture Capital, Loyal Valley Capital, and M Ventures (Merck Corporate Strategic Investment Fund).

Contact Information
Business Development:info@multitudetherapeutics.com 

About HySlink Therapeutics（Hyslink）

HySlink Therapeutics focuses on the innovation and development of antibody-drug conjugate linkers and payloads. With our proprietary T-moiety linker technology, we collaborate with numerous partners to co-develop the next generation of antibody-drug conjugates. This technology has gained widespread recognition in academia, including high praise from Dr. Avantika Gupta of Memorial Sloan Kettering Cancer Center in a "highlighted article" published in the April 2023 issue of Cancer Discovery. We have co-published multiple research papers on related projects with our partners in several authoritative journals under the AACR (Cancer Res 2023;83(22):3783-95; Mol Cancer Ther 2023;22(10):1128-43; Mol Cancer Ther 2023;22(9):1013-27). Currently, multiple projects based on this technology have entered the clinical validation stage, achieving preliminary positive outcomes. We firmly believe that this technology will pave new pathways for the development of antibody-drug conjugates, offering patients more effective treatment options. HySlink Therapeutics will continue to dedicate itself to the innovation and development of antibody-drug conjugates, contributing to the global biopharmaceutical field.

Contact Information
Business Development:bd@hyslink.com